**Preliminary Scientific program**

**Thursday, February 6**

13:30-16:45  **Pre-meeting workshops**

(See details in “Workshops Hands on” section:)

17:00-18:00  **Satellite Symposia**

18:30-19:00  **Opening address and presentation**

  *A. Klee (CH)*

19:00-19:40  **Opening Lectures**

  *Chairmen: C Black (UK), F Wollheim (S)*

  **Two-years in Review-What’s new since Madrid: the Cutting Edge**

  19:00  The clinical overview

  *M Matucci Cerinic (I)*

  19:20  The basic and translational l overview

  *J Varga (USA)*

  Patient representative
Friday, February 7

08:00-09:20 **Session 1 - Management and assessment of newly diagnosed SSc**
Chairmen: van Laar J (UK), N Damjanov (SR)

08:00-  What to do for a patient with newly diagnosed SSc?
- How to assess a patient with new onset of possible systemic sclerosis
- What are the standard of care tests in early SSc patient
- What are the baseline factors of poor prognosis in very early and early SSc
  *P Clements (USA)*

Chairmen: F Van den Hoogen (NL), S Johnsson (CAN)

08:20 NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE
  *S Jordan et al (CH)*

08:30 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS AN AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM COLLABORATIVE INITIATIVE
  *J Pope et al (UK)*

08:40 PERFORMANCE OF THE OLD 1980 ACR AND THE NEW ACR-EULAR SYSTEMIC SCLEROSIS (SSC) CLASSIFICATION CRITERIA IN PATIENTS WITH LIMITED CUTANEOUS SSC
  *P Carreira et al (E)*

08:50 EARLY ACCRUAL OF ORGAN DAMAGE IN SCLERODERMA: RATIONALE FOR DERIVATION AND VALIDATION OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS
  *T Tay et al (AUS)*

09:00 PERFORMANCE OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A SINGLE CENTER SETTING
  *R Dobrota et al (R)*

09:10 SSC INTRINSIC SUBSET CLASSIFICATION IN PATIENTS THAT DEMONSTRATE CLINICAL IMPROVEMENT DURING TREATMENT
  *M Whitfield et al (USA)*

09:20–10:10 **Session 2 – Miscellaneous and differential diagnosis of SSc**
Chairmen: U Walker (CH), R Silver (USA)

09:20 How to differentiate SSc from scleroderma-like disorder ?
- Criteria for very early and early diagnosis of SSc
- Differential diagnoses to be presented including IgG4 syndromes, Shulman, nephrogenic fibrosis, borreliosis
  *A Tyndall (CH)*

09:40 GENDER EFFECTS ON SYSTEMIC SCLEROSIS PHENOTYPE: A LONGITUDINAL EUSTAR STUDY BASED ON MORE THAN 10 000 PATIENTS
  *M Elhai et al (F)*
Continue Friday, February 7

09:50  EPIDEMIOLOGY OF CANCER IN SYSTEMIC SCLEROSIS. SYSTEMATIC REVIEW AND META-ANALYSIS OF CANCER INCIDENCE, PREDICTORS AND MORTALITY
  S Johnson et al (CAN)

10:00  JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY
  J Avouac et al (F)

10:10-10:30  Coffee break

10:30-11:00  Session 3 – The great debate
  Chairmen: G Valentini (I), B Maurer (CH)
  The place of Corticosteroids in SSc
  T Medsger (USA) & J Seibold (USA)

11:00-12:00  poster tour

12:00-13:30  Satellite Symposia

13:30-14:30  Lunch

14:30-15:30  Satellite Symposia

15:30–16:30  Session 4 - An integrated approach to gastro-intestinal involvement
  Chairmen: A Herrick(UK), T Frech (USA)

15:30  GI: How to evaluate, diagnose and treat upper and lower GI involvement
  U Mueller-Ladner (D)

15:50  New therapeutic approaches
  C Murray (UK)

16:10  MORTALITY, RECURRENCE AND HOSPITAL COURSE OF PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) RELATED ACUTE INTESTINAL PSEUDO-OBSTRUCTION
  C Derk et al (USA)

16:20  PREVALENCE, CORRELATES AND OUTCOMES OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS: A EUSTAR CASE-CONTROL STUDY
  E Ghrenassia et al (F)
Session 5 – PARALLEL SESSION BASIC
Links to inflammation, immunity and vascular disease
Chairmen: J Distler (D), D Abraham (UK)

15:30 Immunological mechanisms of fibrosis
T Wynn (USA)

15:50 PIGMENT EPITHELIUM DERIVED FACTOR SECRETED BY SSC FIBROBLASTS INHIBITS ANGIO AND VASCULOGENESIS IN VITRO
V Liakouli et al (I)

16:00 SCLERODERMA DERMAL FIBROBLASTS OVEREXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR DUE TO AUTOCRINE TRANSFORMING GROWTH FACTOR ETA SIGNALING
I Kajihara et al (J)

16:10 IL6 TRANS-SIGNALING AND CCL2 CO-REGULATE FIBROBLAST DEPENDENT TRANS-ENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA.
R Alade et al (UK)

16:20 THE GLOBAL MICRORNA PROFILE OF SKIN IN SYSTEMIC SCLEROSIS
G Salazar et al (USA)

Coffee break

Session 6 – Biologics and novel therapies in SSc
Chairmen: R Simms (USA), C Beyer (D)

Use of biologics in SSc—indications and future perspective
- An update on the use of biologics in SSc
- Benefit/risk ratio of the main molecules
- Upcoming trials
Y Allanore (F)

17.15-17.45 Session 7 - Treatment and DMARDS in SSc
Chairman: P Sampaio Barros (BRA), M Kuwana (JPN)

How to treat rapidly progressive SSc
C Denton (UK)

Session 8 – PARALLEL SESSION Mechanism of fibrosis
Chairmen: A Gabrielli (I), R Lafyatis (USA)

Biomechanical Signaling of Myofibroblast Activation
V Thannickal (USA)
17:05 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) REGULATES TRANSFORMING GROWTH FACTOR-BETA INDUCED FIBROSIS IN SYSTEMIC SCLEROSIS
B Sumova et al (D)

17:15 INVESTIGATING THE ROLE OF MYOCARDIN RELATED TRANSCRIPTION FACTOR (MRTF) IN SYSTEMIC SCLEROSIS (SSC)
X Shiwen et al (UK)

17:25 EPHRIN B2 IS OVEREXPRESSED IN HUMAN SCLERODERMA SKIN AND MEDIATES FIBROBLAST TO MYOFIBROBLAST DIFFERENTIATION AND INDUCES FIBROSIS IN MICE
M Kapoor et al (CAN)

17:35 EXPERIMENTAL RENAL INJURY IN A TGFBETA DEPENDENT MOUSE MODEL OF SCLERODERMA
E Derrett-Smith et al (UK)

17:45 DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE PROTECTS ALVEOLAR EPITHELIAL CELLS FROM APOPTOSIS IN A BLEOMYCIN MODEL OF SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE
G Bogatkevich et al (USA)
Saturday, February 8

08:00-09:00  **Session 9 – Meet the Professors session**
- Approach to SSc-Related Cardiac Disease  
  *L Czirjak (H) & Y Allanore (F)*
- Approach to Kidney Management  
  *L Guillemin (F) & C. Denton (UK)*
- Approach to Ulcer Therapy  
  *M Vonk (NL) & S Guiducci (I)*
- Approach to Therapy of Tendon & Joint Inflammation  
  *M Mayes (USA)*
- Approach to GI management  
  *M Fox (CH)*

09:00–09:40  **Session 10 - Cardiovascular involvement**  
Chairmen: M Inanc (TR), A Vacca (I)

09:00  
Conduction and Rhythm defects in scleroderma  
*C Meune (F)*

09:20  
IMPROVEMENT OF DIGITAL ULCERATIVE DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS IS ASSOCIATED WITH BETTER FUNCTIONAL PROGNOSIS  
*L Mouthon et al (F)*

09:30  
PREDICTION OF CARDIAC AND VASCULAR EVENTS IN SYSTEMIC SCLEROSIS: INPUT FROM ENDOTHELIN-1 TYPE A RECEPTOR ANTIBODIES  
*J Avouac et al (F)*

9:40–10:30  **Session 11 - Interstitial lung disease**  
Chairmen: M Baron (CA), O Kowal Bielecka (PL)

09:40  
SSc-ILD: Who to treat and how to treat?  
- Discuss natural history and disease progression in ILD  
- How to identify patients who require immunosuppressive therapy  
- Efficient drugs and predictors of response  
  *D. Khanna (USA)*

10:00  
PROGRESSIVE DETERIORATION OF PATIENTS WITH SCLERODERMA WITH PULMONARY INVOLVEMENT: 11-YEAR OUTCOMES FROM THE SCLERODERMA LUNG STUDY (SLS1)  
*K Sullivan et al (USA)*
10:10  SURVIVAL AFTER LUNG TRANSPLANTATION IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW  
        S Johnson et al (CAN)

10:20  GENETIC MARKERS OF SUSCEPTIBILITY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS  
        PATIENTS: AN IMMUNOCHIP STUDY  
        L Bossini-Castillo et al (E)

10:30-10:45  Coffee break

10:45-11:55  **Session 12 - Pulmonary Arterial Hypertension**

Chairmen: V Steen (USA), E Hachulla (F)

10:45  PAH: How to make the right diagnosis at the right time
    - Risk factors and predictors of PAH
    - Criteria guiding the clinician to refer the patient for catheterisation
    - How to interpret catheterisation  
        O Distler (D)

Chairmen: M Hinchcliff (USA), S Sato (JPN)

11:05  CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION AND A  
        PULMONARY CAPILLARY WEDGE PRESSURE >15 IN THE PHAROS REGISTRY  
        L Saketkoo et al (USA)

11:15  RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE-TISSUE DISEASE  
        ASSOCIATED PULMONARY ARTERIAL HYPERTENSION  
        D Khanna et al (USA)

11:25  A COMPARISON OF THE PREDICTIVE ACCURACY OF THREE SCREENING MODELS (DETECT V. ESC/ERS  
        V. ASIG) FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS  
        Y J Hao et al (AUS)

11:35  CLINICAL SUBTYPE AND AUTOANTIBODIES BOTH HELP PREDICT PULMONARY ARTERIAL  
        HYPERTENSION BUT AUTOANTIBODIES ARE STRONGER PREDICTORS OF DEVELOPING SECONDARY  
        PULMONARY HYPERTENSION  
        R Domsic et al (USA)

11:45  PROGNOSTIC VALUE OF NT-PROBNP IN SYSTEMIC SCLEROSIS PATIENTS WITHOUT PULMONARY  
        HYPERTENSION  
        M Antivalle et al (I)

11:55-12.10  **Special Lecture**

Chairman: F Del Galdo (UK), G Riemekasten (D)

**Desscipher, a jump in the future!**  
        U Mueller Ladner (D)
12:10-12:30  **Summary of the congress**  
Chairman: L Guillevin (F)  

*Speaker: D Furst (USA)*

12:30-13:00  **Closing ceremony**